Published in J Clin Endocrinol Metab on July 01, 2008
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab (2012) 2.25
Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab (2010) 1.93
Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril (2009) 1.92
Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab (2008) 1.82
Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab (2012) 1.67
Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol (2011) 1.56
Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endocrinol Metab (2008) 1.55
Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer (2010) 1.38
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause (2012) 1.35
Impact of cancer therapies on ovarian reserve. Fertil Steril (2011) 1.28
Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol (2012) 1.24
Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer (2010) 1.18
Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric (2012) 1.14
Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles? PLoS One (2012) 1.07
Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev (2015) 1.06
The ageing ovary and uterus: new biological insights. Hum Reprod Update (2012) 1.04
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril (2012) 1.01
Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod (2009) 0.99
Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci (2010) 0.99
Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol (2009) 0.97
Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol (2013) 0.93
Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Hum Reprod (2011) 0.91
Menstruation and the menopausal transition. Obstet Gynecol Clin North Am (2011) 0.91
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) (2011) 0.91
Neuroendocrine control of the transition to reproductive senescence: lessons learned from the female rodent model. Neuroendocrinology (2012) 0.90
Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis. Menopause (2012) 0.89
Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril (2012) 0.89
The reproductive endocrinology of the menopausal transition. Steroids (2011) 0.89
The effect of diet and cardiovascular risk on ovarian aging in cynomolgus monkeys (Macaca fascicularis). Menopause (2010) 0.88
Experimental induction of reduced ovarian reserve in a nonhuman primate model (Macaca fascicularis). Comp Med (2010) 0.88
Serum antimüllerian hormone predicts ovarian reserve in a monkey model. Menopause (2009) 0.87
Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am (2011) 0.86
Pregnancy after cancer: results from a prospective cohort study of cancer survivors. Pediatr Blood Cancer (2013) 0.86
Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system. Menopause (2012) 0.86
Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers (2016) 0.86
Hormone changes associated with the menopausal transition. Minerva Ginecol (2009) 0.84
Differential effects of aging on estrogen negative and positive feedback. Am J Physiol Endocrinol Metab (2011) 0.84
Anti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundability. Am J Epidemiol (2012) 0.83
Reproductive capacity in iron overloaded women with thalassemia major. Blood (2011) 0.83
Possible novel biomarkers of organ involvement in systemic lupus erythematosus. Clin Rheumatol (2014) 0.83
Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle. Hum Reprod (2013) 0.82
Evaluation of ovarian reserve in infertile patients. J Turk Ger Gynecol Assoc (2012) 0.82
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One (2013) 0.81
Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol (2012) 0.81
Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women. Am J Reprod Immunol (2014) 0.81
Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann N Y Acad Sci (2010) 0.81
Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk. Cancer Prev Res (Phila) (2015) 0.79
Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol (2013) 0.79
Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors. Hum Reprod (2016) 0.78
Weight loss increases follicle stimulating hormone in overweight postmenopausal women [corrected]. Obesity (Silver Spring) (2014) 0.78
The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril (2015) 0.78
Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. Stem Cell Res Ther (2017) 0.78
Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline. BMC Med (2016) 0.78
A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer (2014) 0.77
Endocrine profile of an ovariectomized cynomolgus monkey (Macaca fascicularis) with a supernumerary ovary. Comp Med (2011) 0.77
Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod (2016) 0.77
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab (2015) 0.76
Association of Ovary-Sparing Hysterectomy With Ovarian Reserve. Obstet Gynecol (2016) 0.76
Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. J Assist Reprod Genet (2013) 0.76
An analysis of the influence of selected genetic and hormonal factors on the occurrence of depressive symptoms in late-reproductive-age women. Int J Environ Res Public Health (2015) 0.75
Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA. Reprod Biol Endocrinol (2016) 0.75
Compensatory Increase in Ovarian Aromatase in Older Regularly Cycling Women. J Clin Endocrinol Metab (2015) 0.75
A long way is ahead of prediction of menopause! Int J Endocrinol Metab (2012) 0.75
Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas (2017) 0.75
Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF? J Hum Reprod Sci (2017) 0.75
Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod (1992) 3.66
Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod (2002) 3.59
The variability of female reproductive ageing. Hum Reprod Update (2002) 3.52
Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril (2002) 3.03
Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril (2005) 2.90
Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause (2004) 2.69
Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology (1999) 2.42
Early follicular antimüllerian hormone as an indicator of ovarian reserve. Fertil Steril (2006) 2.29
Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology (2001) 2.28
Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed (2004) 2.23
Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab (1987) 2.21
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril (2002) 2.10
Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod (2006) 2.03
A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod (1996) 1.88
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril (2004) 1.81
Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) (2002) 1.67
Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab (1999) 1.52
Menstrual patterns leading to the final menstrual period. Menopause (2002) 1.49
Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril (2005) 1.47
Circulating immunoreactive inhibin levels during the normal human menstrual cycle. J Clin Endocrinol Metab (1987) 1.26
Dimeric inhibin: a direct marker of ovarian aging. Fertil Steril (1998) 1.19
Joint influence of fat and lean body composition compartments on femoral bone mineral density in premenopausal women. Am J Epidemiol (1992) 1.17
Production of anti-Müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology (1984) 1.16
Developmental and endocrine aspects of normal ovarian aging. Mol Cell Endocrinol (1998) 1.10
Genetic markers, bone mineral density, and serum osteocalcin levels. J Bone Miner Res (1999) 1.07
Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril (1999) 1.07
Regulable expression of inhibin A in wild-type and inhibin alpha null mice. Mol Endocrinol (2000) 1.07
Regulation and function of inhibins in the normal menstrual cycle. Semin Reprod Med (2004) 1.00
Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) (1998) 0.98
Inhibin and reproductive aging in women. Maturitas (1998) 0.97
Inhibin A, inhibin B and activin A in the follicular fluid of regularly cycling women. Hum Reprod (1997) 0.91
Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab (1998) 0.89
Ovarian ageing and postponement of childbearing. Maturitas (1998) 0.84
Haplotype-based association analysis via variance-components score test. Am J Hum Genet (2007) 2.93
Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord (2007) 2.74
Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab (2006) 2.40
Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause (2009) 2.33
Conditional estimation for generalized linear models when covariates are subject-specific parameters in a mixed model for longitudinal measurements. Biometrics (2004) 2.26
Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab (2006) 2.01
Clinical features of progressive vacuolar hepatopathy in Scottish Terriers with and without hepatocellular carcinoma: 114 cases (1980-2013). J Am Vet Med Assoc (2014) 1.99
Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril (2009) 1.92
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet (2009) 1.87
Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab (2008) 1.82
Osteoarthritis of the knee: comparison of MR imaging findings with radiographic severity measurements and pain in middle-aged women. Radiology (2005) 1.74
Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry (2010) 1.73
Does risk for anxiety increase during the menopausal transition? Study of women's health across the nation. Menopause (2013) 1.72
Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression. Am J Hum Genet (2011) 1.71
Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum (2006) 1.71
Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab (2006) 1.67
Racial/ethnic differences in the prevalence of depressive symptoms among middle-aged women: The Study of Women's Health Across the Nation (SWAN). Am J Public Health (2004) 1.61
Complete androgen insensitivity syndrome--a review. J Pediatr Adolesc Gynecol (2008) 1.60
Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endocrinol Metab (2008) 1.55
Ethnic differences in past hysterectomy for benign conditions. Womens Health Issues (2005) 1.52
Reductions in glucose among postmenopausal women who use and do not use estrogen therapy. Menopause (2013) 1.50
Gene-trait similarity regression for multimarker-based association analysis. Biometrics (2009) 1.44
Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination. Urology (2002) 1.43
A Monte Carlo EM algorithm for generalized linear mixed models with flexible random effects distribution. Biostatistics (2002) 1.40
Vacuolar hepatopathy in dogs: 336 cases (1993-2005). J Am Vet Med Assoc (2006) 1.40
Evaluation of urine sulfated and nonsulfated bile acids as a diagnostic test for liver disease in dogs. J Am Vet Med Assoc (2003) 1.39
How do intoxicated patients impact staff in the emergency department? An exploratory study. N Z Med J (2011) 1.38
Associations of anatomical measures from MRI with radiographically defined knee osteoarthritis score, pain, and physical functioning. J Bone Joint Surg Am (2011) 1.37
The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab (2010) 1.27
A hot-deck multiple imputation procedure for gaps in longitudinal data on recurrent events. Stat Med (2008) 1.23
Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab (2009) 1.22
Bias due to left truncation and left censoring in longitudinal studies of developmental and disease processes. Am J Epidemiol (2011) 1.21
Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). J Clin Endocrinol Metab (2012) 1.15
Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr (2006) 1.15
Smoothing spline-based score tests for proportional hazards models. Biometrics (2006) 1.14
Performance-based physical functioning in African-American and Caucasian women at midlife: considering body composition, quadriceps strength, and knee osteoarthritis. Am J Epidemiol (2006) 1.11
Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires. Menopause (2013) 1.10
Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab (2010) 1.09
The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab (2006) 1.07
Change in adipocytokines and ghrelin with menopause. Maturitas (2008) 1.04
Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J Clin Endocrinol Metab (2003) 1.04
Analysis of a binary composite endpoint with missing data in components. Stat Med (2007) 1.04
A new statistical approach demonstrated menstrual patterns during the menopausal transition did not vary by age at menopause. J Clin Epidemiol (2004) 1.03
Variable selection for semiparametric mixed models in longitudinal studies. Biometrics (2009) 1.02
Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab (2012) 1.00
Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc (2005) 1.00
Oestrogen metabolites in relation to isoprostanes as a measure of oxidative stress. Clin Endocrinol (Oxf) (2007) 0.99
Gallbladder disease in Shetland Sheepdogs: 38 cases (1995-2005). J Am Vet Med Assoc (2007) 0.99
Relating smoking, obesity, insulin resistance, and ovarian biomarker changes to the final menstrual period. Ann N Y Acad Sci (2010) 0.99
Androgens are associated with hemostatic and inflammatory factors among women at the mid-life. J Clin Endocrinol Metab (2005) 0.99
The association of bone mineral density with estrogen receptor gene polymorphisms. Am J Med (2006) 0.98
Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril (2003) 0.98
Sarcopenia is related to physical functioning and leg strength in middle-aged women. J Gerontol A Biol Sci Med Sci (2005) 0.98
Automatic Model Selection for Partially Linear Models. J Multivar Anal (2009) 0.98
The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol (2008) 0.97
MR imaging evaluation of acute appendicitis in pregnancy. Radiology (2006) 0.97
Menopausal transition stage-specific changes in circulating adrenal androgens. Menopause (2012) 0.96
Likelihood and Pseudo-likelihood Methods for Semiparametric Joint Models for a Primary Endpoint and Longitudinal Data. Comput Stat Data Anal (2007) 0.95
Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause (2008) 0.95
Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN). Am J Med (2006) 0.95
Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab (2005) 0.94
Racial differences in women who have a hysterectomy for benign conditions. Womens Health Issues (2009) 0.93
Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis". Arch Intern Med (2008) 0.93
Hormonal environment affects cognition independent of age during the menopause transition. J Clin Endocrinol Metab (2012) 0.92
Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med (2006) 0.91
Estrogen receptor genotypes and their association with the 10-year changes in bone mineral density and osteocalcin concentrations. J Clin Endocrinol Metab (2004) 0.91
Physical functioning among mid-life women: associations with trajectory of depressive symptoms. Soc Sci Med (2010) 0.90
Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab (2012) 0.90
Characterizing daily urinary hormone profiles for women at midlife using functional data analysis. Am J Epidemiol (2007) 0.90
Dietary intake related to prevalent functional limitations in midlife women. Am J Epidemiol (2008) 0.90
Dietary fat subgroups, zinc, and vegetable components are related to urine F2a-isoprostane concentration, a measure of oxidative stress, in midlife women. J Nutr (2007) 0.88
Lead in breast milk and maternal bone turnover. Am J Obstet Gynecol (2002) 0.88
Mineralocorticoid before glucocorticoid deficiency in a dog with primary hypoadrenocorticism and hypothyroidism. J Am Anim Hosp Assoc (2012) 0.88
Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease? Menopause (2013) 0.87
Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am (2011) 0.86
Genetic polymorphisms and obesity influence estradiol decline during the menopause. Clin Endocrinol (Oxf) (2011) 0.85
Validation of a new multiplex assay against individual immunoassays for the quantification of reproductive, stress, and energetic metabolism biomarkers in urine specimens. Am J Hum Biol (2011) 0.84
Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist (2013) 0.84
Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period. J Clin Endocrinol Metab (2013) 0.84
Serum 25 hydroxyvitamin D, bone mineral density and fracture risk across the menopause. J Clin Endocrinol Metab (2015) 0.83
Influence of dietary supplementation with (L)-carnitine on metabolic rate, fatty acid oxidation, body condition, and weight loss in overweight cats. Am J Vet Res (2012) 0.83
Role stress, role reward, and mental health in a multiethnic sample of midlife women: results from the Study of Women's Health Across the Nation (SWAN). J Womens Health (Larchmt) (2012) 0.83